留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

应中央军委要求,2022年9月起,《药学实践杂志》将更名为《药学实践与服务》,双月刊,正文96页;2023年1月起,拟出版月刊,正文64页,数据库收录情况与原《药学实践杂志》相同。欢迎作者踊跃投稿!

选择性雌激素受体调节剂研究现状

丁浩 杨帆 蔡艺 柴晓云 吴秋业

丁浩, 杨帆, 蔡艺, 柴晓云, 吴秋业. 选择性雌激素受体调节剂研究现状[J]. 药学实践与服务, 2016, 34(1): 1-4,55. doi: 10.3969/j.issn.1006-0111.2016.01.001
引用本文: 丁浩, 杨帆, 蔡艺, 柴晓云, 吴秋业. 选择性雌激素受体调节剂研究现状[J]. 药学实践与服务, 2016, 34(1): 1-4,55. doi: 10.3969/j.issn.1006-0111.2016.01.001
DING Hao, YANG Fan, CAI Yi, CHAI Xiaoyun, WU Qiuye. Research progress on the selective estrogen receptor modulators[J]. Journal of Pharmaceutical Practice and Service, 2016, 34(1): 1-4,55. doi: 10.3969/j.issn.1006-0111.2016.01.001
Citation: DING Hao, YANG Fan, CAI Yi, CHAI Xiaoyun, WU Qiuye. Research progress on the selective estrogen receptor modulators[J]. Journal of Pharmaceutical Practice and Service, 2016, 34(1): 1-4,55. doi: 10.3969/j.issn.1006-0111.2016.01.001

选择性雌激素受体调节剂研究现状

doi: 10.3969/j.issn.1006-0111.2016.01.001

Research progress on the selective estrogen receptor modulators

  • 摘要: 乳腺癌已经成为危害女性健康的主要恶性肿瘤,选择性雌激素受体调节剂作为治疗乳腺癌的有效药物越来越受到人们的广泛关注。笔者对选择性雌激素受体调节剂的研究现状进行综述。
  • [1] Advani P, Moreno-Aspitia A. Current strategies for the prevention of breast cancer[J], Breast Cancer (Dove Med Press), 2014, 6: 59-71.
    [2] 郑 莹, 吴春晓, 吴 凡, 等. 中国女性乳腺癌死亡现况和发展趋势[J]. 中华预防医学杂志, 2011, 45(2): 150-154.
    [3] Fan L, Strasser-Weippl K, Li JJ, et al. Breast cancer in China[J]. Lancet Oncol, 2014, 15(7): 279-289.
    [4] Germain D. Estrogen carcinogenesis in breast cancer[J]. Endocrinol Metab Clin North Am, 2011, 40(3): 473-484.
    [5] Nelson ER, Wardell SE, McDonnell DP. The molecular mechanisms underlying the pharmacological actions of estrogens, SERMs and oxysterols: Implications for the treatment and prevention of osteoporosis[J]. Bone, 2013, 53(1): 42-50.
    [6] Ortona E, Pierdominici M, Berstein L. Autoantibodies to estrogen receptors and their involvement in autoimmune diseases and cancer[J]. J Steroid Biochem Mol Biol, 2014, 144: 260-267.
    [7] Osborne CK, Schiff R. Estrogen-receptor biology: continuing progress and therapeutic implications[J]. J Clin Oncol, 2005, 23: 1616-1622.
    [8] Mirkin S, Pickar JH. Selective estrogen receptor modulators (SERMs): A review of clinical data[J]. Maturitas, 2015, 53: 52-57.
    [9] Nagaraj G, Ma C. Revisiting the estrogen receptor pathway and its role in endocrine therapy for postmenopausal women with estrogen receptor-positive metastatic breast cancer[J]. Breast Cancer Res Treat, 2015,150(2):231-242.
    [10] Shanle EK, Xu W. Endocrine disrupting chemicals targeting estrogen receptor signaling: identification and mechanisms of action[J]. Chem Res Toxicol, 2011, 24: 6-19.
    [11] Komm BS, Mirkin S. An overview of current and emerging SERMs[J]. J Steroid Biochem Mol Biol, 2014, 143:207-222.
    [12] Williams C, Lin CY. Oestrogen receptors in breast cancer: basic mechanisms and clinical implications[J]. Ecancermedicalscience, 2013, 7:370.
    [13] Hadji P. The evolution of selective estrogen receptor modulators in osteoporosis therapy[J]. Climacteric, 2012, 15 (6): 513-523.
    [14] Maximov PY, Lee TM, Jordan VC. The discovery and development of selective estrogen receptor modulators (SERMs) for clinical practice[J]. Curr Clin Pharmacol, 2013, 8(2): 135-155.
    [15] Jordan VC, McDaniel R, Agboke F, et al. The evolution of nonsteroidalantiestrogens to become selective estrogen receptor modulators[J]. Steroids, 2014, 90: 3-12.
    [16] Kaur G, Mahajan MP, Pandey MK. Design, synthesis and evaluation of Ospemifene analogs as anti-breast cancer agents[J]. Eur J Med Chem, 2014, 86: 211-218.
    [17] Silverman S, Christiansen C. Individualizing osteoporosis therapy[J]. Osteoporos Int, 2012, 23 (3): 797-809.
    [18] Gennari L, Merlotti D, Stolakis K, et al. Lasofoxifene, from the preclinicaldrug discovery to the treatment of postmenopausal osteoporosis[J]. Expert Opin Drug Discov, 2011, 6 (2): 205-217.
    [19] Michalsen BT, Gherezghiher TB, Choi J, et al. The selective estrogen receptor modulator (SERM) Lasofoxifeneformsreactive quinonessimilar to estradiol[J]. Chem Res Toxicol, 2012, 25(7) : 1472-1483.
    [20] Vessières A, Top S, Beck W, et al. Metal complex SERMs (selective estrogen receptor modulators). The influence of different metal units on breast cancer cell antiproliferativeeffects[J]. Dalton Trans, 2006, 4: 529-541.
    [21] Li M J, Greenblatt HM, Dym O, et al. Structure of estradiol metal chelate and estrogen receptor complex: The basis for designing a new class of selective estrogen receptor modulators[J]. J Med Chem, 2011, 54(10): 3575-3580.
    [22] Top S, Vessi res A, Leclercq G, et al. Synthesis, biochemical properties and molecular modelling studies of organometallic specific estrogen receptor modulators (SERMs), the ferrocifens and hydroxyferrocifens: evidence for an antiproliferative effect of hydroxyferrocifens on both hormone-dependent and hormone-independent breast cancer cell lines[J]. Chemistry, 2003, 9(21): 5223-5236.
    [23] Plazuk D, Vessi res A, Hillard EA, et al. A[3]ferrocenophane polyphenol showing a remarkable antiproliferative activity on breast and prostate cancer cell lines[J]. J Med Chem, 2009, 52(15): 4964-4967.
    [24] Jain N, Kanojia RM, Xu J, et al. Novelchromene-derived selective estrogen receptor modulators usefulfor alleviating hot flushes and vaginal dryness[J]. J Med Chem, 2006, 49(11): 3056-3059.
    [25] Jain N, Xu J, Kanojia RM, et al. Identification and structure-activity relationships of chromene-derived selective estrogen receptor modulators for treatment of postmenopausal symptoms[J]. J Med Chem, 2009, 52: 7544-7569.
    [26] Paterni I, Granchi C, Katzenellenbogen JA, et al. Estrogen receptors alpha (ERα) and beta (ERβ): subtype-selectiveligands and clinicalpotential[J]. Steroids, 2014, 90: 13-29.
    [27] Kim S, Wu JY, Birzin ET, et al. Estrogen Receptor Ligands. II. Discovery of benzoxathiins as potent, selective estrogen receptorαmodulators[J]. J Med Chem, 2004, 47(9): 2171-2175.
    [28] Liao ZQ, Dong C, Carlson KE, et al. Triaryl-substitutedschiff bases are high-affinity subtype-selective ligands for the estrogenreceptor[J]. J Med Chem, 2014, 57: 3532-3545.
    [29] Carroll VM, Jeyakumar M, Carlson KE, et al. Diarylpropionitrile (DPN) enantiomers: synthesis and evaluation of estrogen receptor β-selective ligands[J]. J Med Chem, 2012, 55: 528-537.
    [30] Ohta K, Ogawa T, Kaise A, et al. Aliphatic substitution of ocarboranyl phenols enhances estrogen receptor beta selectivity[J]. Chem Pharm Bull, 2014, 62: 386-391.
  • [1] 董雅芬, 王建, 陈业, 李姝姝, 刘河龙, 邱彦.  雌激素干预的EPCs移植对糖尿病缺血性脑卒中大鼠的治疗作用 . 药学实践与服务, 2023, 41(1): 40-44, 49. doi: 10.12206/j.issn.2097-2024.202111111
    [2] 董雅芬, 王建, 李莉, 李姝姝, 刘河龙, 邱彦.  雌激素对糖尿病大鼠内皮祖细胞功能的影响及其机制研究 . 药学实践与服务, 2022, 40(4): 320-325. doi: 10.12206/j.issn.1006-0111.202106121
    [3] 江海龙, 王宁远, 陆一鸣.  肿瘤坏死因子受体选择性拮抗剂的研究进展 . 药学实践与服务, 2015, 33(5): 392-395. doi: 10.3969/j.issn.1006-0111.2015.05.003
    [4] 王羽, 范宇平, 胡烨, 黄文强, 滕晓明.  联合激素治疗低促性腺激素性腺功能低下青春期发育迟滞 . 药学实践与服务, 2013, 31(5): 357-358,395. doi: 10.3969/j.issn.1006-0111.2013.05.010
    [5] 王洋, 郑唯强.  雌激素及三苯氧胺对MCF-7乳腺癌细胞BP1基因表达的影响 . 药学实践与服务, 2005, (4): @-@.
    [6] 杨泉海, 王霞.  激素替代疗法及其安全性 . 药学实践与服务, 2003, (5): 263-266.
    [7] 蒙诚跃, 梁自乾, 王润秀, 张立明, 李德绘, 覃桂萍.  应用人重组生长激素治疗大面积烧伤疗效的观察 . 药学实践与服务, 2001, (6): 326-327.
    [8] 陈建明, 叶丽卡, 高申, 毛世瑞, 毕殿洲.  褪黑激素明胶微球剂与溶液剂鼻粘膜给药比较 . 药学实践与服务, 2001, (5): 280-281.
    [9] 张新萍, 贾骏骅.  激素治疗中的药物经济学分析 . 药学实践与服务, 1999, (1): 7-8.
    [10] 周建设, 史荣组.  生长激素临床应用进展 . 药学实践与服务, 1997, (3): 143-144,150.
    [11] 柳正良, 李名秀, 崔志平.  高效离子对液相色谱法测定促甲状腺激素释放激素(TRH)血药浓度的研究 . 药学实践与服务, 1995, (4): 234-236.
    [12] 郑希林.  雌激素的临床应用近况 . 药学实践与服务, 1993, (3): 170-171.
    [13] 孙向伟, 周明非.  运动员中雄性激素的滥用 . 药学实践与服务, 1992, (2): 60-61.
    [14] 石兴华, 徐峰.  糖皮质激素药物的不良又应:国内文献复习 . 药学实践与服务, 1991, (4): 56-58.
    [15] 景凡伟, 张紫洞.  雌激素是骨质疏松最佳的治疗 . 药学实践与服务, 1989, (2): 19-19.
    [16] 吡丁醇—支气管扩张药(选择性β2—肾上腺素受体激动剂) . 药学实践与服务, 1988, (4): 34-34.
    [17] 刘月娥, 胡兴钰.  大剂量局部注射皮质激素引起溶骨性骨坏死 . 药学实践与服务, 1986, (4): 33-34.
    [18] 王俊华.  雌性激素口腔溃疡药膜通过鉴定 . 药学实践与服务, 1985, (4): 75-75.
    [19] 合理用药讨论会会务组.  肾上腺皮质激素的合理应用 . 药学实践与服务, 1985, (1): 9-13.
    [20] R.J.Plumridge.  确保局部用皮质激素的合理使用 . 药学实践与服务, 1984, (4): 29-30.
  • 加载中
计量
  • 文章访问数:  3428
  • HTML全文浏览量:  280
  • PDF下载量:  137
  • 被引次数: 0
出版历程
  • 收稿日期:  2014-10-13
  • 修回日期:  2015-06-05

选择性雌激素受体调节剂研究现状

doi: 10.3969/j.issn.1006-0111.2016.01.001

摘要: 乳腺癌已经成为危害女性健康的主要恶性肿瘤,选择性雌激素受体调节剂作为治疗乳腺癌的有效药物越来越受到人们的广泛关注。笔者对选择性雌激素受体调节剂的研究现状进行综述。

English Abstract

丁浩, 杨帆, 蔡艺, 柴晓云, 吴秋业. 选择性雌激素受体调节剂研究现状[J]. 药学实践与服务, 2016, 34(1): 1-4,55. doi: 10.3969/j.issn.1006-0111.2016.01.001
引用本文: 丁浩, 杨帆, 蔡艺, 柴晓云, 吴秋业. 选择性雌激素受体调节剂研究现状[J]. 药学实践与服务, 2016, 34(1): 1-4,55. doi: 10.3969/j.issn.1006-0111.2016.01.001
DING Hao, YANG Fan, CAI Yi, CHAI Xiaoyun, WU Qiuye. Research progress on the selective estrogen receptor modulators[J]. Journal of Pharmaceutical Practice and Service, 2016, 34(1): 1-4,55. doi: 10.3969/j.issn.1006-0111.2016.01.001
Citation: DING Hao, YANG Fan, CAI Yi, CHAI Xiaoyun, WU Qiuye. Research progress on the selective estrogen receptor modulators[J]. Journal of Pharmaceutical Practice and Service, 2016, 34(1): 1-4,55. doi: 10.3969/j.issn.1006-0111.2016.01.001
参考文献 (30)

目录

    /

    返回文章
    返回